Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10774)	7/13/1999 9:16:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 17367

I am not sure what you mean by the "50% placebo thing", but the following from the xoma.com FAQ may be relevant: <<Is the pivotal trial placebo-controlled? How many patients will be in the control group? What does "double-blind" mean? (2/99) The meningococcemia Phase III study is double-blinded, randomized and placebo-controlled. Patients are randomly assigned to either receive NEUPREX®, or an inert substance (a "placebo"). Approximately equal numbers of patients will be in each group. Both groups also receive the same standard care including antibiotics, often in an intensive care setting. "Double-blinded" means that neither the treating physician nor the sponsoring company knows which patients receive the drug and which receive placebo until the study is concluded and the blind broken. We will not know which patients received NEUPREX® until after the trial is complete and the data are checked and verified.>>

To: Robert K. who wrote (10774)	7/13/1999 9:31:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacaito, explained why we can't count on an even 50/50 split. but for analysis or speculation on results one ends up putting the same number in each arm. Look, here is how I see the impact of the SOC in the U.K. The bottle tumbler test gets lots of aware parents to get there kids treated fast. Attending docs. carry the antibiotic most used. The less aware barely get their kids in before they die and many of them did. Perhaps someday we will se how many of the 62 were from the U.K and how many from Canada/U.S. Such a hypothesis would lower the mortality rate. When adjusted for the 62 the mortality rate climbs to over 30% and even when one assumes there were another 62 who refused to enter the trial and lived the mortality rate still remains at 25% for those not treated with Neuprex. 79/259 or 79/321 Note that in both cases only 17 of the total deaths of those enrolled in the trial are assigned to the placebo arm, so if Neuprex worked the death rate for those not getting Neuprex is higher.

To: Robert K. who wrote (10774)	7/13/1999 9:31:00 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Hey Bob, remember this?>>>>>>>>>>>>Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP. 10 Claims, 26 Drawing Figures<<<<<<<<<< Now what percent of shareholders even know this exists?LOL Please explain it to us now that you have seen the Baboon abstract on the possible potent antibacterial effects of rBPI21.